AKT1
|
Proteus syndrome
| NA (somatic) | Focal somatic overgrowth, epidermal nevi, vascular malformations, dysplastic adipose tissue | Cerebriform connective tissue nevi & postnatal onset of overgrowth (vs congenital onset in PROS). Absence of characteristic truncal fatty-vascular mass, spinal paraspinal fast-flow lesions, acral abnormalities of CLOVES syndrome |
AKT3
CCND2
PIK3R2
|
Megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndrome
| AD (de novo) or somatic | Brain overgrowth (MEG), polymicrogyria, hydrocephalus, polydactyly, connective tissue or joint laxity | Absence of consistent vascular/lymphatic malformations or severe focal somatic overgrowth |
HRAS
KRAS
NRAS
| Linear nevus sebaceous syndrome (LNSS) (OMIM 163200) | NA (somatic) | Cutaneous findings (incl epidermal nevi & vascular malformations) | Absence of significant tissue overgrowth or more widespread vascular/lymphatic malformations |
MTOR
| Smith-Kingsmore syndrome (SKS) (OMIM 616638) | AD (de novo) or somatic | Brain overgrowth (MEG), polymicrogyria, cutaneous findings (incl hyperpigmented nevi) | Absence of consistent vascular/lymphatic malformations |
PTCH1
SUFU
|
Basal cell nevus syndrome
| AD | Brain overgrowth (MEG), polydactyly, syndactyly | Calcine calcification, BCCs, jaw cysts, epidermal cysts, wide ribs, many other skeletal & other multisystem features |
PTEN
| PTEN hamartoma tumor syndrome (PHTS) | AD | Brain overgrowth (MEG), vascular malformations (incl capillary malformations), lipomas | Intestinal hamartomas, pigmented macules of the penis, absence of significant focal somatic overgrowth, acral deformities, ↑ cancer risk of specific cancer types |
SOLAMEN syndrome (phenotypic subtype of PHTS) | See footnote 1. | Segmental overgrowth, lipomatosis, arteriovenous malformation, epidermal nevi | ↑ cancer risk (ovarian cystadenoma, multiple breast tumors, thyroid adenomas), fibrocystic breast disease, gingival papules, multinodular goiter |
TSC1
TSC2
| Tuberous sclerosis complex (TSC) | AD | Brain overgrowth (MEG, HMEG, FCD) | Absence of striking focal overgrowth & consistent vascular/lymphatic malformations; presence of white nevi, shagreen patches, ↑ multisystem cancer risk |